الفهرس 
Review of literatureيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 133 |  |  |
| | | from | 133 | | |
المستخلص
Acute lymphoblastic leukemia (ALL) is the most common form of childhood leukemia. In childhood ALL, molecular studies can provide diagnostic and prognostic information with a direct impact on patient management. Numerous genetic and molecular factors involved in pathogenesis of the disease create a lot of problems in management of pediatric ALL. Nowadays, clinicians are hoping to take a right decision, choose a proper less toxic regimen for the patient. It was found that the hallmarks of the treatment of childhood ALL is the reliance on risk-based stratification. By identifying the features that have been shown to affect prognosis, patients can be classified into groups based on risk of treatment failure. Recently, miRNAs studies showed that aberrant expression of miRNAs can be used as signatures of acute lymphoblastic leukemia (ALL) with differ¬ent subtypes and predict drug resistance. The present study was conducted on 45 child diagnosed as ALL patients, PB samples were collected priory to therapy. Molecular analysis using (RQ-PCR) technique was applied for detection of miRNA-155 and miRNA-181a genes expression levels before and post chemotherapy induction; this was done assess their role as indicators to monitor disease prognosis and outcome. Clinical and hematological data were collected from patient files to assess their response to induction chemotherapy. from this study, we may conclude that: miR155 and miR181a are good diagnostic and prognostic biomarkers for childhood ALL and have a potent role in leukemogensis of pediatric ALL.miRNA-155 is a good predictor for pediatric ALL, provide clinically relevant insight into the efficacy of treatment, predicts clinical outcome and allows discrimination between low and high-risk patients than conventional prognostic factors. Therefore, it can be incorporated into stratification decision of treatment protocols. Marked decrease in the miR155 and miR181a genes expression after therapy could reflect their impact on disease outcome and that they can be therapeutically targeted.